<div id="readability-page-1"><p>Cytek Biosciences, Inc. ((CTKB)) has held its Q1 earnings call. Read on for the main highlights of the call.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Cytek Biosciences’ latest earnings call struck a cautiously optimistic tone, as management highlighted a solid start to 2026 with steady revenue growth, a strong rebound in the U.S. and expanding recurring revenue, while also acknowledging margin pressure and a wider net loss. The company framed higher legal and operating costs, regional disruptions and FX impacts as near-term headwinds on what it described as an improving long-term trajectory toward profitability.</p> <h2>Revenue Growth and Constructive Start to 2026</h2> <p>Cytek posted Q1 2026 revenue of $44.1 million, up 6% from $41.5 million a year ago, describing the quarter as a constructive start to the year. Management said the performance reflects a return to more normalized U.S. market conditions after prior volatility, giving them confidence in the demand environment despite regional pockets of softness.</p> <h2>Strong U.S. Performance</h2> <p>U.S. revenue surged to $24.4 million, a 32% year-over-year increase from $18.5 million, making the region the clear growth engine for the quarter. The company credited broad-based instrument demand from academic labs, biopharma customers and repeat buyers, suggesting that core customers are actively investing in Cytek’s platforms.</p> <h2>Recurring Revenue Momentum</h2> <p>Trailing 12-month combined reagents and service revenue reached $18.4 million, representing 35% of total revenue and growing 19% year-over-year. Management emphasized this recurring stream as a key stabilizer for the business, pointing to rising adoption of reagents and service contracts as evidence that customers are becoming more deeply embedded in Cytek’s ecosystem.</p> <h2>Services and Reagents Double-Digit Growth</h2> <p>Service revenue climbed 15% year-over-year to $15.4 million, while reagent revenue grew in the mid-teens, with management citing a 16% increase. Reagent demand was particularly strong in APAC and the rest of the world, where growth exceeded 40% year-over-year, underscoring robust consumables and service attachment outside the company’s core U.S. base.</p> <h2>Installed Base and Unit Growth</h2> <p>Cytek added 125 instruments in Q1, bringing its installed base to 3,789 units, as total instrument volume grew 9% year-over-year. FSP instrument units increased 3%, and management portrayed the expanding installed base as a foundation for future recurring revenue from reagents, service and software.</p> <h2>Product Adoption: Aurora and Cytek Cloud</h2> <p>Revenue from the Aurora analyzer category rose about 8% year-over-year following the launch of the Aurora Evo, signaling continued demand for the flagship system. The company also highlighted that Cytek Cloud has surpassed 26,000 users, or roughly eight users per installed FSP instrument, reinforcing the growing importance of software and cloud engagement in its offering.</p> <h2>Balance Sheet Strength</h2> <p>Cytek ended the quarter with $262.2 million in cash, cash equivalents and marketable securities, slightly up from $261.5 million at year-end 2025. Management stressed that this balance sheet strength provides ample flexibility to fund growth initiatives and navigate near-term earnings volatility without sacrificing strategic investments.</p> <h2>Affirmed Full-Year Guidance and Path to Profitability</h2> <p>The company reaffirmed its full-year 2026 revenue outlook of $205 million to $212 million, implying 2% to 5% growth, and expects adjusted EBITDA to improve each quarter. Management reiterated its goal of delivering positive adjusted EBITDA for the full year, framing 2026 as a transition period toward sustainable profitability supported by recurring revenue and operating leverage.</p> <h2>Regional Headwinds in EMEA</h2> <p>EMEA revenue fell 7% year-over-year to $10.8 million, as the region faced disruptions tied to conflict in the Middle East and shipment delays late in the quarter. Executives framed these issues as largely external and timing-related, but the softness underlined that Cytek’s growth is not evenly distributed across geographies.</p> <h2>APAC Decline Driven by China Order Timing</h2> <p>APAC revenue, including China, declined 13% year-over-year, which management attributed primarily to order timing after customers accelerated purchases in China in the prior-year Q1. They noted that APAC excluding China showed strong growth, suggesting underlying demand remains healthy once the order timing distortion is removed.</p> <h2>Gross Margin Pressure</h2> <p>GAAP gross margin slipped to 48% from 49%, while adjusted gross margin eased to 51% from 52%, reflecting modest pressure on profitability at the gross level. Service gross margin was slightly lower due to higher labor costs, indicating that wage and staffing investments are weighing on margins even as services grow.</p> <h2>Rising Operating Expenses</h2> <p>Total operating expenses rose 13% year-over-year to $39.7 million, with general and administrative costs jumping 43%, or $5.6 million. Management pointed to higher legal expenses, outside consulting and increased bad debt reserves as the main drivers, signaling that non-core costs are currently outpacing revenue growth.</p> <h2>Wider GAAP Net Loss and Lower Adjusted EBITDA</h2> <p>The company’s GAAP net loss widened to $18.9 million from $11.4 million in the prior-year quarter, underscoring the earnings drag from rising costs. Adjusted EBITDA loss also expanded to $9.1 million from $3.3 million, a setback management linked largely to the step-up in operating expenses rather than to a deterioration in top-line demand.</p> <h2>Patent Litigation and Legal Costs</h2> <p>A significant increase in legal spending tied to ongoing patent litigation contributed meaningfully to the surge in G&amp;A expenses. While management portrayed these legal costs as temporary, they acknowledged that the actions are creating near-term cost pressure and uncertainty around the timing and scale of potential relief.</p> <h2>Foreign Exchange and Tax Headwinds</h2> <p>Other income was pressured by a $1.2 million foreign exchange loss, reversing a $1.3 million FX gain in the prior year and weighing on the bottom line. Tax expense climbed to $1.5 million from $0.1 million, adding another layer of headwind and helping explain why the net loss grew more than operating trends alone would suggest.</p> <h2>Instrument Product Revenue Moderation</h2> <p>Product revenue, which includes instruments and reagents, increased only about 2% year-over-year to $28.8 million as instrument demand softened in some regions. Management linked the moderation to regional weakness and order timing effects, emphasizing that they expect services and reagents to shoulder more of the growth burden near term.</p> <h2>Forward-Looking Guidance and Outlook</h2> <p>Looking ahead, Cytek’s guidance assumes continued strength in services and reagents, with instruments delivering flat to modest growth and a buffer for macroeconomic risks. Management expects gross margins to improve as revenue builds seasonally and reiterated that adjusted EBITDA should trend higher each quarter, culminating in a positive full-year 2026 result backed by a solid cash position.</p> <p>Cytek’s earnings call painted a picture of a company balancing strong commercial momentum with short-term profitability challenges. Investors are likely to focus on whether recurring revenue and U.S. growth can offset regional and legal headwinds, and on management’s ability to convert a growing installed base into sustainable earnings as 2026 progresses.</p></div>

CTKB

LABU

<p>Cytek Biosciences reported Q1 2026 revenue of $44.1 million, a 6% increase year-over-year, driven by strong U.S. performance and recurring revenue growth. Despite margin pressures and a wider net loss, management remains optimistic about long-term profitability. The company reaffirmed its full-year revenue guidance of $205 million to $212 million. Regional challenges were noted in EMEA and APAC, with gross margins slightly declining due to rising operating expenses. Cytek's balance sheet remains strong, with $262.2 million in cash, allowing for continued investment in growth initiatives.</p>

Cytek Biosciences Balances Growth Momentum With Cost Pressures